Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors

Creative Commons License

Sahin U., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, ss.1697-1706, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 50
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/sag-1911-112
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1697-1706
  • Anahtar Kelimeler: Graft-versus-tumor effect, recipient derived immune effector cells, allogeneic hematopoietic stem cell transplantation, solid tumors, STEM-CELL TRANSPLANTATION, BONE-MARROW-TRANSPLANTATION, HIGH-DOSE CHEMOTHERAPY, INTENSITY CONDITIONING REGIMENS, RECIPIENT LYMPHOCYTE INFUSION, REDUCED-INTENSITY, T-CELLS, BREAST-CANCER, OVARIAN-CANCER, EUROPEAN GROUP
  • Ankara Üniversitesi Adresli: Evet

Özet

Background/aim: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model following allo-HSCT from other strains of mice, graft-versus-tumor (GvT) effect in a solid tumor after allo-HSCT has also been reported in a murine model in 1984. Several trials have reported the presence of a GvT effect in patients with various refractory solid tumors, including renal, ovarian and colon cancers, as well as soft tissue sarcomas Ill. The growing data on haploidentical transplants also indicate GvT effect in some pediatric refractory solid tumors. Novel immunotherapy-based treatment modalities aim at inducing an allo-reactivity against the metastatic solid tumor via a GvT effect. Recipient derived immune effector cells (RDICs) in the antitumor reactivity following allo-HSCT have also been considered as an emerging therapy for advanced refractory solid tumors.